AT384549B - Process for the preparation of a vaccine - Google Patents

Process for the preparation of a vaccine

Info

Publication number
AT384549B
AT384549B AT3985A AT3985A AT384549B AT 384549 B AT384549 B AT 384549B AT 3985 A AT3985 A AT 3985A AT 3985 A AT3985 A AT 3985A AT 384549 B AT384549 B AT 384549B
Authority
AT
Austria
Prior art keywords
cells
vaccine
pigment
animals
spots
Prior art date
Application number
AT3985A
Other languages
German (de)
Other versions
ATA3985A (en
Original Assignee
Strasser Engelbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strasser Engelbert filed Critical Strasser Engelbert
Priority to AT3985A priority Critical patent/AT384549B/en
Publication of ATA3985A publication Critical patent/ATA3985A/en
Application granted granted Critical
Publication of AT384549B publication Critical patent/AT384549B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The invention relates to a process for the preparation of a vaccine against ageing and against benign tumours of the spleen, which is characterized in that the vaccine is prepared by injecting pigment-containing human ageing cells (liver spots, age spots) of the epidermis (basal cell layer) or pigment-containing cells of the corium (connective tissue), where appropriate with the addition of human spleen cells, into animals and obtaining the immune serum from the blood of these animals, the initial injection preferably being into horses (three times at weekly intervals, subcutaneously to intramuscularly).

Description

  

   <Desc/Clms Page number 1> 
 



   Die Erfindung bezieht sich auf ein Verfahren zur Herstellung einer Vaccine gegen das Altern und bezweckt die Alterung zu verlangsamen, ohne schädigende Nebenwirkungen zu verursachen. 



   Wesen der Erfindung ist, dass pigmentstoffhaltige menschliche Alterungszellen (Leberflecke,
Altersflecken) der Epidermis (Basalzellschicht) sowie pigmentstoffhältige Zellen des Coriums (Bin- degewebe) gegebenenfalls unter Zusatz von menschlichen Milzzellen als Ausgangsmaterial in Tiere eingespritzt werden, vorzugsweise in Pferde (dreimal im Abstand von je einer Woche, subkutan bis intramuskulär), und dass aus deren Blut das Serum gegen das Altern gewonnen wird (nach
Standardmethoden). (Serumabsorbation an Aluminiumhydroxyd). Als Ausgangsmaterial werden nur Alterungszellen verwendet, keine gesunden pigmentstoffhältigen Zellen wie Sommersprossen oder sonnengebräunte Haut und auch keine entarteten Zellen wie Melanomzellen und auch keine andern Muttermalzellen und Melanosarkomzellen. 



   Die Erfindung ist auch nicht auf eine Tiergattung zur Impfstoffgewinnung beschränkt. 



   Dieser Impfstoff wird in zwei Varianten hergestellt :
Variante 1 : Pigmentstoffhältige Zellen der Epidermis (Leberflecke, Alterungsflecke) und des Coriums des Menschen werden in Tiere eingespritzt und aus deren Blut wird der Impfstoff gegen das Altern hergestellt. 



   Variante 2 : Pigmentstoffhältige Zellen der Epidermis (Altersflecke, Leberflecke) und des Coriums (Bindegewebe) und gesunde Milzzellen des Menschen werden in Tiere eingespritzt und deren Blut wird ebenfalls zur Impfstoffgewinnung verwendet. 



   Wirkungsweise :
Variante 1 wirkt auf das Retico-Endothel-System stark stimulierend und fördert die Ausbildung von Antikörpern durch das Immunsystem gegen Alterungszellen und Pigmentstoffe im Körper, wobei es den Antikörpertiter gegen Alterungszellen des mit dem Serum behandelten Menschen stark erhöht und deren Abbau fördert. 



   Variante 2 wird hauptsächlich gegen chronische Milztumore angewendet, aber nicht gegen Anthrax. 



   Aus der US-PS Nr. 4, 046, 722 ist ein Verfahren bekannt, wobei Melanomzellen als Ausgangsmaterial zur Herstellung von Immun-Globulin (Ig) gegen Melanome verwendet werden. 



   Auch die der US-PS Nr. 4, 414, 148 sowie Proc. Nat. Acad. Sci. 1980,77 (4) 2183 bis 2187 entnehmbare Antikörperbildung beziehen sich auf Melanome und Karzinome anderer Art und gehen von Melanomzellen als Ausgangsmaterialien aus. 



   Melanomzellen werden bei der erfindungsgemässen Impfstoffgewinnung nicht eingesetzt. 



   Die erhaltenen Vaccinen wirken nicht gegen Melanome. Die erfindungsgemäss hergestellten Vaccinen bewirken neben der Antikörperbildung gegen Alterungsstoffe - nicht allein gegen melaninhältige Zellen - auch eine vermehrte Bildung von Histiozyten in den Milchflecken (milk spots) und eine vermehrte Ausschüttung von Thymozyten in den Blutstrom. 

**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.



   <Desc / Clms Page number 1>
 



   The invention relates to a method for producing a vaccine against aging and the purpose of which is to slow aging without causing harmful side effects.



   The essence of the invention is that human aging cells (liver spots,
Age spots) of the epidermis (basal cell layer) and pigment-containing cells of the corium (connective tissue) may be injected into animals, preferably with the addition of human spleen cells, as a starting material, preferably in horses (three times at intervals of one week, subcutaneously to intramuscularly), and that whose blood the serum is obtained against aging (after
Standard methods). (Serum absorption on aluminum hydroxide). Only aging cells are used as the starting material, no healthy pigment-containing cells such as freckles or sun-tanned skin and also no degenerate cells such as melanoma cells and also no other birthmark cells and melanosarcoma cells.



   The invention is also not limited to an animal species for vaccine production.



   There are two versions of this vaccine:
Variant 1: Pigment-containing cells of the epidermis (liver spots, aging spots) and the corium of humans are injected into animals and the vaccine against aging is made from their blood.



   Variant 2: pigment-containing cells of the epidermis (age spots, liver spots) and the corium (connective tissue) and healthy spleen cells of humans are injected into animals and their blood is also used to obtain vaccines.



   Mode of action:
Variant 1 has a strong stimulating effect on the retico-endothelium system and promotes the formation of antibodies by the immune system against aging cells and pigment substances in the body, whereby it greatly increases the antibody titer against aging cells of the people treated with the serum and promotes their breakdown.



   Variant 2 is mainly used against chronic spleen tumors, but not against anthrax.



   A method is known from US Pat. No. 4,046,722, in which melanoma cells are used as starting material for the production of immunoglobulin (Ig) against melanomas.



   Also that of US Pat. Nos. 4, 414, 148 and Proc. Nat. Acad. Sci. 1980.77 (4) 2183 to 2187 removable antibody formation refer to melanomas and carcinomas of other types and start from melanoma cells as starting materials.



   Melanoma cells are not used in the vaccine production according to the invention.



   The vaccines obtained have no effect on melanomas. In addition to the formation of antibodies against aging substances - not only against melanin-containing cells - the vaccines produced according to the invention also cause an increased formation of histiocytes in the milk spots (milk spots) and an increased release of thymocytes into the blood stream.

** WARNING ** End of DESC field may overlap beginning of CLMS **.

Claims (1)

PATENTANSPRUCH : Verfahren zur Herstellung einer Vaccine gegen das Altern und gegen benigne Milztumore, dadurch gekennzeichnet, dass zur Herstellung des Impfstoffes pigmentstoffhältige menschliche Alterungszellen (Leberflecke, Altersflecken) der Epidermis (Basalzellschicht) bzw. pigmentstoffhältige Zellen des Coriums (Bindegewebe), gegebenenfalls unter Zusatz von menschlichen Milzzellen, in Tiere eingespritzt werden und dass aus dem Blut dieser Tiere das Immunserum gewonnen wird, wobei die anfängliche Einspritzung vorzugsweise in Pferde (dreimal im Abstand von je einer Woche, subkutan bis intramuskulär) erfolgt. **WARNUNG** Ende CLMS Feld Kannt Anfang DESC uberlappen**.   PATENT CLAIM: Process for the preparation of a vaccine against aging and against benign spleen tumors, characterized in that for the production of the vaccine pigment-containing human aging cells (liver spots, age spots) of the epidermis (basal cell layer) or pigment-containing cells of the corium (connective tissue), optionally with the addition of human spleen cells , are injected into animals and that the immune serum is obtained from the blood of these animals, the initial injection preferably taking place in horses (three times at intervals of one week, subcutaneously to intramuscularly). ** WARNING ** End of CLMS field knows overlap beginning of DESC **.
AT3985A 1985-01-08 1985-01-08 Process for the preparation of a vaccine AT384549B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT3985A AT384549B (en) 1985-01-08 1985-01-08 Process for the preparation of a vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT3985A AT384549B (en) 1985-01-08 1985-01-08 Process for the preparation of a vaccine

Publications (2)

Publication Number Publication Date
ATA3985A ATA3985A (en) 1987-05-15
AT384549B true AT384549B (en) 1987-11-25

Family

ID=3479910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT3985A AT384549B (en) 1985-01-08 1985-01-08 Process for the preparation of a vaccine

Country Status (1)

Country Link
AT (1) AT384549B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046722A (en) * 1975-02-04 1977-09-06 G. D. Searle & Co. Limited Immunological materials
US4414148A (en) * 1981-04-15 1983-11-08 Sanofi Anti-cancer drugs for the treatment of melanomas and method for preparing thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046722A (en) * 1975-02-04 1977-09-06 G. D. Searle & Co. Limited Immunological materials
US4414148A (en) * 1981-04-15 1983-11-08 Sanofi Anti-cancer drugs for the treatment of melanomas and method for preparing thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC. NAT. ACAD. SCI. 1980, 77(4), 2183 BIS 2187 *

Also Published As

Publication number Publication date
ATA3985A (en) 1987-05-15

Similar Documents

Publication Publication Date Title
DE69830582T2 (en) USE OF LACTOFERRINE IN THE TREATMENT OF COMPLAINTS CAUSED BY ALLERGENS
DE60129585T2 (en) TRANSDERMALE DEVICE
DE3806565C2 (en)
DE3712767A1 (en) IMMUNOLOGICAL ADJUVANS
DE19923427A1 (en) Device for improved delivery of active agents to skin, useful e.g. for administering opiates, contains agent that increases local skin temperature or blood flow
DE2517452A1 (en) COVERING FILM FOR COSMETIC APPLICATION
EP0363835B1 (en) Use of zinc or iron hydroxide in the adjuvation of antigen solutions, and antigen solutions adjuvated in this manner
AT384549B (en) Process for the preparation of a vaccine
DE69532964T2 (en) NEW PROTEINS FROM EKTOPARASITESSPEICHEL AND DEVICE FOR COLLECTION THEREOF
DE10024383A1 (en) Dendritic cells loaded with toxic substances
DE69837350T2 (en) TOPICAL IMMUNOSTIMULATION FOR INDUCING MIGRATION OF LONG HANS CELLS
DE2814121C3 (en) Process for the preparation of a specific immune serum useful in cancer diagnosis K K Saikin Kagaku Kenkyujo, Sendaishi
DE4007315A1 (en) Use of zinc-calcium hydroxide gel, lecithin and poly-alpha-olefin! - as adjuvants to increase immunogenicity of antigens, are of low toxicity and work synergistically
DE2405002B2 (en) Soluble native collagen from human plantain and agents containing this as a therapeutic agent
DE2646625C2 (en)
DE2532934C3 (en) Plankton products from sulphurous thermal springs, processes for their production and their cosmetic use
EP0040604B1 (en) Cosmetic preparation
EP0281647B1 (en) Organic compounds for the enlargement of female breasts
DE1617332B2 (en) Method for isolating a water-soluble protein-metal chelate with anti-inflammatory activity
WO2019092257A1 (en) Microneedle system for applying a hepatitis vaccine
DE112009002431T5 (en) Application of Fc fragments of immunoglobulin G as an antigen for the treatment of rheumatoid arthritis, treatment agents and methods of treatment
DE2515666A1 (en) NEW PROTEIN PRODUCT, ITS PRODUCTION AND USE
DE2064604C3 (en) Skin care products
DE307975C (en)
Neuhaus et al. Hepatic production of serum alpha2 and beta globulins in rats after injury

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
REN Ceased due to non-payment of the annual fee